prasugrel Articles
STEMI guidelines now recommend AstraZeneca's ticagrelor as first-line treatment option
30 August 2012
Proposal to fund Lilly’s Effient in New Zealand
21 February 2012
Brazilian acute coronary syndrome drug market set to nearly double to $229 million in 2015
1 December 2011
China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015
22 November 2011
Ranbaxy launches branded generic prasugrel in India
10 June 2010
Bristol-Myers Squibb says USPTO to review Plavix patent
20 August 2009
Daiichi/Lilly's Efient gets first world launch in UK - first new antiplatelet drug in a decade
9 April 2009
Erratum: Daiichi Sankyo US approval for Effient
9 April 2009
Japan stock market week to April 6, 2009
7 April 2009
Stock Commentary - New York week to March 23, 2009
30 March 2009
Japan stock market week to Feb 9, 2009
16 February 2009
Japan stock market week to Jan 12, 2009
19 January 2009
Japan stock market week to Jan 5, 2009
12 January 2009
Japan stock market week to Oct 27, 2008
3 November 2008
Stock Commentary - New York week to Oct 6, 2008
13 October 2008
Japan stock market week to August 4, 2008
11 August 2008
Lilly's 2nd-qtr rise hides coming challenges
4 August 2008
Japan stock market week to May 19, 2008
26 May 2008
Japan stock market week to Feb 25, 2008
3 March 2008
Tokyo stocks to January 7, 2008
14 January 2008
Daiichi Sankyo and Eli Lilly submit NDA to US FDA for prasugrel; to be sold as Effient
14 January 2008
Showing 1-32 of 32 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
